Polypharmacy among Patients with Diabetes Mellitus Attending the Diabetic Clinic, National Hospital, Galle.

Show simple item record

dc.contributor.author Lakshika, D.M.K.
dc.contributor.author Gunawardana, K.B.
dc.contributor.author Mendis, S.A.
dc.contributor.author Liyanage, P.L.G.C.
dc.date.accessioned 2026-09-16T07:12:32Z
dc.date.available 2026-09-16T07:12:32Z
dc.date.issued 2026-03-04
dc.identifier.citation A en_US
dc.identifier.issn 2362-0412
dc.identifier.uri http://ir.lib.ruh.ac.lk/handle/iruor/21782
dc.description.abstract Patients with diabetes mellitus are at a higher risk of exposure to polypharmacy due to the presence of multiple comorbid conditions, which heavily impact their overall health outcomes. This study aimed to assess the prevalence, appropriateness, associated factors, and impact of polypharmacy on diabetic patients. A cross-sectional study was conducted among 290 patients aged≥ 18 years with type 1 or type 2 diabetes attending the diabetic clinic at the National Hospital, Galle. Data were extracted from clinic record books and from both self-administered and interview-administered questionnaires. Polypharmacy was defined as taking five or more medications per day. The appropriateness of polypharmacy was analyzed by two expert clinicians. Descriptive statistics, chi-square tests, odds ratios, and logistic regression were performed using SPSS version 25, with a significance level of p < 0.05. The mean age of the study population was 59.2 years (SD = 11.03), and patients were prescribed an average of 5.88 medications (SD = 2.43). The prevalence of polypharmacy was 69% (200/290). Inappropriate polypharmacy was observed in 12.4% of participants (36/290). Polypharmacy was significantly associated with multimorbidity (p < 0.05), including hypertension (OR = 4.49; 95% CI: 2.633–7.675), dyslipidaemia (OR = 3.60; 95% CI:2.107–6.146), asthma (OR = 8.27; 95% CI:1.083–63.117), and heart failure (OR = 11.00; 95% CI: 1.459– 82.93). Lipid-modifying (86.3%) and antithrombotic drugs (63.1%) were the most frequently prescribed in combination with antidiabetic medications. The prevalence of polypharmacy showed a significant association with age (p < 0.001), duration of treatment (p < 0.001), and low knowledge about medications (p = 0.002). Polypharmacy had a significant impact on forgetfulness, difficulty in managing cost, adverse side effects, healthcare utilization barriers, medication adherence, and patient dissatisfaction with their treatments (p < 0.001). In conclusion, the study revealed a high prevalence of polypharmacy among patients with diabetes, and the findings indicate the importance of continuous medication review, improving prescribing practices, and enhancing patient education to minimize inappropriate polypharmacy and optimize therapeutic outcomes. en_US
dc.language.iso en en_US
dc.publisher Faculty of Engineering , University of Ruhuna, Sri Lanka. en_US
dc.subject Diabetes mellitus en_US
dc.subject Multimorbidity en_US
dc.subject Polypharmacy en_US
dc.subject Inappropriate polypharmacy en_US
dc.title Polypharmacy among Patients with Diabetes Mellitus Attending the Diabetic Clinic, National Hospital, Galle. en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account